There is evidence that NPC is susceptible to immunotherapeutic approaches, as the adoptive transfer of EBV-specific T cells or blockade of the PD-L1/PD-1 checkpoint has led to tumor responses and disease control in some patients with refractory disease [8–10]. The gene discussed is PDCD1; the disease is neoplasm.